Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013731" target="_blank" >RIV/00023736:_____/24:00013731 - isvavai.cz</a>

Alternative codes found

RIV/00023001:_____/24:00085332 RIV/00216224:14110/24:00138221 RIV/61988987:17110/24:A2503AL4 RIV/00216208:11110/24:10486518 and 13 more

Result on the web

<a href="https://doi.org/10.4244/EIJ-D-24-00203" target="_blank" >https://doi.org/10.4244/EIJ-D-24-00203</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4244/EIJ-D-24-00203" target="_blank" >10.4244/EIJ-D-24-00203</a>

Result language

angličtina

Original language name

Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial

Original language description

Cardiogenic shock (CS) is a devastating and fatal complication of acute myocardial infarction (AMI). CS can affect the pharmacokinetics and pharmacodynamics of medications. The unique properties of cangrelor make it the optimal P2Y12 inhibitor for CS-AMI, in terms of both efficacy and safety. The DAPT-SHOCK-AMI trial (ClinicalTrials.gov: NCT03551964, EudraCT: 2018-002161-19) will assess the benefits of cangrelor in patients with an initial CS-AMI undergoing primary angioplasty. This randomised, multicentre, placebo-controlled trial of approximately 550 patients (with an allowed 10% increase) in 5 countries using a double-blind design will compare initial P2Y12 inhibitor treatment strategies in patients with CS-AMI of (A) intravenous cangrelor and (B) ticagrelor administered as crushed tablets at a loading dose of 180 mg. A platelet reactivity study that tests the laboratory antiplatelet benefits of cangrelor, when given in addition to standard antiplatelet therapy, will be conducted using vasodilator-stimulated phosphoprotein phosphorylation. The primary laboratory endpoints are the periprocedural rate of onset and the proportion of patients who achieve effective P2Y12 inhibition. The DAPT-SHOCK-AMI study is the first randomised trial to evaluate the benefits of cangrelor in patients with CS-AMI.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

EuroIntervention

ISSN

1774-024X

e-ISSN

—

Volume of the periodical

20

Issue of the periodical within the volume

20

Country of publishing house

FR - FRANCE

Number of pages

10

Pages from-to

—

UT code for WoS article

001367392800008

EID of the result in the Scopus database

2-s2.0-85207594400